Nelly Joseph-Mathurin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7054058/publications.pdf

Version: 2024-02-01

687363 677142 43 838 13 22 citations g-index h-index papers 46 46 46 1433 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. Nature Medicine, 2020, 26, 398-407.	30.7	351
2	Comparison of Pittsburgh compound B and florbetapir in crossâ€sectional and longitudinal studies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 180-190.	2.4	84
3	In Vivo Cross-sectional Characterization of Cerebral Alterations Induced by Intracerebroventricular Administration of Streptozotocin. PLoS ONE, 2012, 7, e46196.	2.5	83
4	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS ONE, 2016, 11, e0152082.	2.5	45
5	Variant-dependent heterogeneity in amyloid \hat{l}^2 burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. Lancet Neurology, The, 2022, 21, 140-152.	10.2	34
6	Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds. Neurobiology of Aging, 2013, 34, 2613-2622.	3.1	32
7	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. Neurobiology of Disease, 2020, 142, 104960.	4.4	31
8	Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease. Neurolmage, 2022, 256, 119228.	4.2	27
9	Micro-MRI Study of Cerebral Aging: Ex Vivo Detection of Hippocampal Subfield Reorganization, Microhemorrhages and Amyloid Plaques in Mouse Lemur Primates. PLoS ONE, 2013, 8, e56593.	2.5	22
10	Widespread white matter and conduction defects in PSEN1-related spastic paraparesis. Neurobiology of Aging, 2016, 47, 201-209.	3.1	17
11	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. Neurolmage: Clinical, 2020, 28, 102491.	2.7	17
12	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. Neurology, 2021, 96, e1632-e1645.	1.1	16
13	Comparing amyloid- \hat{l}^2 plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. Acta Neuropathologica, 2021, 142, 689-706.	7.7	15
14	Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 669-677.	2.4	14
15	A novel PSEN1 (S230N) mutation causing early-onset Alzheimer's Disease associated with prosopagnosia, hoarding, and Parkinsonism. Neuroscience Letters, 2017, 657, 11-15.	2.1	9
16	Regional Age-Related Atrophy After Screening for Preclinical Alzheimer Disease. Neurobiology of Aging, 2021, 109, 43-51.	3.1	9
17	CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease. Neurobiology of Disease, 2022, 168, 105714.	4.4	7
18	Intracranial internal carotid artery calcification is not predictive of future cognitive decline. Alzheimer's Research and Therapy, 2022, 14, 32.	6.2	6

#	Article	IF	CITATIONS
19	Progressive White Matter Injury in Preclinical Dutch Cerebral Amyloid Angiopathy. Annals of Neurology, 2022, 92, 358-363.	5.3	5
20	Biomarker clustering in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 274-284.	0.8	2
21	IC-P-100: The ILP: A new tool for evaluating preclinical Alzheimer's disease using volumetric MRI in a single participant., 2015, 11, P68-P68.		1
22	Cerebral Amyloid Angiopathy., 2022,, 273-282.		1
23	IC-P-060: REVEALING WHITE MATTER ABNORMALITY BY DIFFUSION TENSOR MAGNETIC RESONANCE IMAGING BEFORE THE ONSET OF DEMENTIA IN ALZHEIMER DISEASE. , 2014, 10, P34-P34.		О
24	O1-01-06: Correlation between ASL and o-15 water PET in the adult children study., 2015, 11, P126-P126.		0
25	IC-P-051: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence. , 2015, 11, P41-P41.		О
26	P2-138: Early frame of PiB and FDG in autosomal dominant Alzheimer's disease: Similarity, discrepancy, and clinical implication., 2015, 11, P538-P538.		0
27	IC-P-052: Comparison of cerebral glucose metabolism 18 F-FDG, early frames of 11 C-PIB,Âand cerebral blood flow 15 O-H2 O in autosomal dominant Alzheimer's disease. , 2015, 11, P41-P41.		0
28	P3-175: The ilp: A new tool for evaluating preclinical Alzheimer's disease using volumetric MRI in a single participant., 2015, 11, P697-P697.		0
29	IC-03-02: Early frame of PiB and FDG in autosomal dominant Alzheimer's disease: Similarity, discrepancy, and clinical implication., 2015, 11, P8-P9.		0
30	P3-132: Comparison of cerebral glucose metabolism 18 F-FDG, early frames of 11 C-PiB, and cerebral blood flow 15 O-H2 O in autosomal dominant Alzheimer's disease., 2015, 11, P674-P674.		0
31	P2-154: Patterns of tau binding in T807-PET imaging. , 2015, 11, P546-P546.		0
32	O2-01-03: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence., 2015, 11, P172-P172.		0
33	ICâ€P‶17: Neuronal Injury and Degeneration Evaluated With Imaging and CSF Biomarkers in Autosomal Dominant AD: Results From The Dian Study. Alzheimer's and Dementia, 2016, 12, P87.	0.8	0
34	P1â€254: Principal Component Analysis of [18F]â€Avâ€1451 TAU Pet in Alzheimer'S Disease and Frontotem Dementia. Alzheimer's and Dementia, 2016, 12, P507.	poral 0.8	0
35	P3â€234: Similarities and Differences in Patterns of [F18]â€AVâ€1451 and [F18]â€FDG in Frontotemporal Deme Alzheimer's and Dementia, 2016, 12, P915.	entia. O.8	O
36	IC-P-204: Principal Component Analysis of [18F]-Av-1451 TAU PET in Alzheimer's Disease and Frontotemporal Dementia. , 2016, 12, P145-P146.		0

#	Article	IF	CITATIONS
37	ICâ€Pâ€206: Similarities and Differences in Patterns of [F18]â€Avâ€1451 And [F18]â€FDG in Frontotemporal Dementia. Alzheimer's and Dementia, 2016, 12, P147.	0.8	O
38	O2â€08â€05: Neuronal Injury and Degeneration Evaluated with Imaging and CSF Biomarkers in Autosomal Dominant Alzheimer's Disease: Results from the Dian Study. Alzheimer's and Dementia, 2016, 12, P246.	0.8	0
39	[ICâ€Pâ€057]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P47.	0.8	O
40	[P2–372]: UTILITY OF PERFUSION PET MODELS AS MEASURES OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P768.	0.8	0
41	[ICâ€Pâ€166]: UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P125.	0.8	0
42	[O1–02–04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P186.	0.8	0
43	ICâ€Pâ€046: CEREBRAL AMYLOID ANGIOPATHY IS MORE SEVERE IN AUTOSOMAL DOMINANT AD CASES WITH CEREBRAL MICROHEMORRHAGES: RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2019, 15, P48.	0.8	O